PLK1 is a potential therapeutic target for the treatment of the poor prognosis-associated triple-negative breast cancer (TNBC) since it was found to be significantly overexpressed in TNBC compared with the other breast cancer subtypes38, 39. Here, PLK1 is linked to breast carcinoma.